AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02912273 — intervention group
Intervention type: OTHER
Intervention: Baseline Healthcare Provider Assessment
Description: * Cognition: Orientation-Memory-Concentration Test which contains 6 questions that the provider will ask the participant. Form items 1-3, the response is either correct (score 0) or incorrect (score 1). For items 4-6, subtract one point for each error. Total score of 11 or greater indicates cognitive impairment (maximum score =28)~* Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~* Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again.
Study NCT02912273 — intervention group
Intervention type: OTHER
Intervention: Follow-up Participant Assessment
Description: * Section 1 contains multiple choice questions about daily actives and several physical function questions~* Section 2 asks the participants how many medications they take on a daily basis, indicate any medication for depression, anxiety, nausea , and other stomach conditions~* Section 3 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling
Study NCT02912273 — intervention group
Intervention type: OTHER
Intervention: Follow-up Healthcare Provider Assessment
Description: * Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~* Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again.
Study NCT02912273 — intervention group
Intervention type: OTHER
Intervention: End-of-study Participant Assessment
Description: * Section 1 contains multiple choice questions about daily actives and several physical function questions~* Section 2 asks the participants how many medications they take on a daily basis, indicate any medication for depression, anxiety, nausea , and other stomach conditions~* Section 3 contains multiple questions about the participant's concern about falling with answers ranging from 1=Not at all to 4=Very~* Section 4 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling
Study NCT02912273 — intervention group
Intervention type: OTHER
Intervention: End-of-study Healthcare Provider Assessment
Description: * Cognition: Orientation-Memory-Concentration Test which contains 6 questions that the provider will ask the participant. Form items 1-3, the response is either correct (score 0) or incorrect (score 1). For items 4-6, subtract one point for each error. Total score of 11 or greater indicates cognitive impairment (maximum score =28)~* Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~* Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again.
Study NCT02071433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saphenous nerve blockade
Study NCT02071433 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve blockade
Study NCT01457183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed lavage (Stryker Pulsavac Plus)
Description: Healthy subjects with intact skin will be lavaged through the device for 1 minute on 3 different sites. The stryker pulsavac plus will be used for the lavage.
Study NCT02437136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: An orally available histone deacetylases inhibitor (HDACs)
Study NCT02437136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: A selective humanized monoclonal antibody (mAb)
Study NCT02823158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of Globus Pallidus internus (GPi) and Best medical treatment (BMT)
Description: Patients in the GPi group will be implanted with DBS-electrodes within 6 weeks after randomisation. The stimulation parameters and the medical treatment are adjusted for optimal control of motor and non-motor signs and symptoms according to published guidelines using a specified algorithm. The stimulation parameters are recorded at the beginning and at the end of each post-surgical assessment.~Best medical treatment is applied in combination with GPi-DBS.
Study NCT02823158 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Best medical treatment
Description: Patients will receive optimized medical treatment according to published evidence based guidelines.
Study NCT02823158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Best medical treatment
Description: Patients will receive optimized medical treatment according to published evidence based guidelines.
Study NCT02399033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xihuang Capsules
Description: In two weeks after hepatectomy, Xihuang Capsules group received Xihuang Capsules (2 g, bid), Continuously taking to cancer recurrence or death.
Study NCT03664128 — intervention group
Intervention type: OTHER
Intervention: Coping with Anxiety through Living Mindfully (CALM) Pregnancy
Description: Mindfulness-based Cognitive Behavioral Therapy (CBT) for perinatal anxiety on a subset (8 participants); no intervention for other participants
Study NCT03162679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills training of Affect-Regulation - A culture-sensitive approach: STARK
Description: Emotion Regulation Group Therapy, 14 sessions, 1.5 hour sessions, group therapy, meeting weekly.
Study NCT02368327 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluad
Study NCT02368327 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fendrix
Study NCT02368327 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02846103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological samples
Description: blood and tumor tissue samples
Study NCT01110252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stem cells stimulation
Description: Subcutaneous injection of 5mcg/kg of G-CSF 3 days before the procedure.
Study NCT01110252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stem cells stimulation
Description: Subcutaneous injection of 5mcg/kg of G-CSF 3 days before the procedure.
Study NCT01110252 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cells collection
Description: pullout of 200ml of bone marrow through the puncture of the iliac crest
Study NCT01110252 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stem cells collection
Description: pullout of 200ml of bone marrow through the puncture of the iliac crest
Study NCT01110252 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: stem cells infusion
Description: slow infusion through the brachial vein of 30ml of bone marrow mononuclear cells diluted in albuminous saline.
Study NCT01110252 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: stem cells infusion
Description: slow infusion through the brachial vein of 30ml of bone marrow mononuclear cells diluted in albuminous saline.
Study NCT00895830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD405
Description: IV
Study NCT01547559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: part1:teprenone
Description: Teprenone 50mg tid after meal for Hp negative patients.
Study NCT01547559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: part1:EAC-T
Description: esomeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily followed by gastric mucosal protective therapy with teprenone 50mg three times daily for 11 weeks
Study NCT01547559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: part1:EA-EMC-T
Description: esomeprazole 20 mg plus amoxicillin 1 g, twice daily for 5 days, then esomeprazole 20 mg with clarithromycin 500 mg and metronidazole 500 mg, twice daily for another 5 consecutive days) followed by teprenone 50mg three times daily until 12 weeks
Study NCT01547559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: part1:teprenone
Description: Teprenone 50mg tid after meal for Hp positive patients.
Study NCT01547559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: part2:GGA group
Description: GGA 50mg three times daily plus diclofenac sodium 75mg once a day for patients with rheumatic diseases.
Study NCT00895830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV
Study NCT04144439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GABA
Description: Gamma amino butyric acid
Study NCT00382031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zalutumumab
Description: Individual dose titration weekly i.v doses
Study NCT00382031 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Best Supportive Care
Study NCT00382031 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Best Supportive Care
Study NCT00808041 — intervention group
Intervention type: DEVICE
Intervention: Dedicated breast computed tomography imaging
Description: Pre- and post-contrast enhancement acquisition of breast CT images of tumor-containing breast every two months.
Study NCT01811147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitor (SSRI)
Description: Subjects with depression will be treated with a Selective Serotonin Reuptake Inhibitor (SSRI) or a Serotonin-norepinephrine reuptake inhibitor (SNRI) for 24 months.
Study NCT04863274 — intervention group
Intervention type: DRUG
Intervention: atorvastatin
Description: Profound patients' consultations (different from standard practice) on the importance of primary prevention of cardiovascular diseases, including preventive administration of statins.~Subjects in profound consultation group will receive regular reminders (2 times a month) via SMS and phone calls to check following the doctor's recommendations and remind about follow-up visit to study centre.
Study NCT03791333 — intervention group
Intervention type: OTHER
Intervention: injury severity score
Description: injury severity score of multi trauma patients
Study NCT04663945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biobehavioral Tele-rehabilitation Sessions
Description: Biobehavioral tele-rehabilitation sessions
Study NCT02630160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrochloride
Description: Intraarticular infusion with bupivacaine
Study NCT02630160 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiological Saline
Description: Intraarticular infusion physiological serum
Study NCT04007315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SaeboGlove therapy
Description: An individualised self-management training programme involving repetitive grasping and releasing movements over 6 weeks.
Study NCT04007315 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: 6-weeks of usual NHS care
Study NCT00565331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: single dose of rituximab of 375 mg/m2 intravenously at the time of transplantation
Study NCT00565331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline solution
Study NCT01976806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study NCT01976806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study NCT01976806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid
Study NCT01976806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Docosahexaenoic acid)
Description: Placebo (corn/soybean oil) capsules manufactured to look identical to DHA capsules
Study NCT01106040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphoseek
Description: The total volume of Lymphoseek injection will be between 0.1 - 1.0 mL.
Study NCT04093596 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ALLO-715
Description: ALLO-715 is an allogeneic CAR T cell therapy targeting BCMA
Study NCT04093596 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-647
Description: ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
Study NCT04093596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for lymphodepletion
Study NCT04093596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for lymphodepletion
Study NCT04093596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: a small molecule, selective, reversible, noncompetitive inhibitor of γsecretase (GSI) that increases BCMA target density on the surface of multiple myeloma cells.
Study NCT01274884 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tightrope fixation
Description: Arthroscopic repair
Study NCT02445547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UC-MSCs by peripheral intravenous infusion
Study NCT02445547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: received hormone maintenance therapy
Study NCT02506933 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03977246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open-placebo
Description: Application of the open-placebo intervention
Study NCT03977246 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Application of the control session
Study NCT02506933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Description: Given IM
Study NCT00508573 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Follow-up questionnaire done once a year for five years.
Study NCT05124223 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac MRI was performed as clinically indicated to assess cardiac pathology.
Study NCT04630379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Therapy
Description: Visit with palliative care team
Study NCT04630379 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palliative Therapy
Description: Visit with palliative care team
Study NCT04630379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04630379 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04630379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Visit with neuro-oncologist
Study NCT04630379 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care
Description: Visit with neuro-oncologist
Study NCT04630379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey
Study NCT04630379 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Complete survey
Study NCT01722513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil ﹠control
Description: control:Normal salin 1cc/kg/hr before and after angiography
Study NCT02963376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.05 mL/kg DDFPe
Description: Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.05 mL/kg based on patient body weight in kilograms (kg).
Study NCT02963376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.05 mL/kg Placebo
Description: Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.05 mL/kg is based on patient body weight in kilograms (kg).
Study NCT02963376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.10 mL/kg DDFPe
Description: Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.10 mL/kg based on patient body weight in kilograms (kg).
Study NCT02963376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.10 mL/kg Placebo
Description: Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.10 mL/kg is based on patient body weight in kilograms (kg).
Study NCT02963376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.17 mL/kg DDFPe
Description: Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.17 mL/kg based on patient body weight in kilograms (kg).
Study NCT02963376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.17 mL/kg Placebo
Description: Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.17 mL/kg is based on patient body weight in kilograms (kg).
Study NCT02506933 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given IM
Study NCT01845363 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cefazolin used in antimicrobial prophylaxis
Description: Cefazolin administered a first dose of 2g in anesthetic induction, followed by continuous dosage of 1g diluted in 250mL of saline solution for two hours.~Two samples of subcutaneous tissue were collected for analysis: the first soon after the incision, and a second before skin synthesis.~The samples were processed by HPLC.
Study NCT02550340 — intervention group
Intervention type: OTHER
Intervention: acute alcohol intake
Description: Smart phone based ECG recording
Study NCT01596166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Ketorolac 0.5 mg/kg (max 30 mg) IV
Study NCT01596166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Metoclopramide 0.2 mg/kg (max 10 mg) IV
Study NCT01596166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoclopramide
Description: Metoclopramide 0.2 mg/kg (max 10 mg) IV
Study NCT04738084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meru Health Program
Description: Each week of the 12 week program follows a different theme. Patients and therapists interact asynchronously after their initial Zoom-based intake call. Psychiatrists and medical doctors are available for consults if needed.
Study NCT04625348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultracore Repose® mattress
Description: residents will be placed on the Ultracore Repose® mattress for the daily care during 14 days
Study NCT04625348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experiences and perceptions of healthcare workers
Description: Three focus groups will be set- up at the end of the study to provide insights into how caregivers think about the product and to provide a deeper understanding of the difference between the use of the Ultracore Repose® mattress (versus the Repose overlay mattress® and an alternating air mattress)
Study NCT02376465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI4600 bowel preparation
Description: Oral bowel preparation for colonoscopy
Study NCT02376465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG based bowel preparation
Description: Oral bowel preparation for colonoscopy
Study NCT01052649 — intervention group
Intervention type: OTHER
Intervention: Blood sampling